Indaptus Therapeutics, Inc.

Clinical/early-stage biotech — oncology clinical micro-cap, thin liquidity.

Strengths

• Liquidity — current ratio 1.5 (19th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• RestatementLazar in compliance with the rules and regulations of Nasdaq (without regard to any limitations on conversion set forth in the applicable Certificate of Designations) upon conversion of the shares of 8-K ↗
• Going concern● We have identified conditions and events that raise substantial doubt regarding our ability to continue as going concern
• Exec changeRecent 8-K item 5.02 8-K ↗
• Buying back stockNet buyback — share count -80%/yr over 2y
• Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)